COMPUTATIONAL OPTIMISATION OF TARGETED DNA SEQUENCING FOR CANCER DETECTION

Size: px
Start display at page:

Download "COMPUTATIONAL OPTIMISATION OF TARGETED DNA SEQUENCING FOR CANCER DETECTION"

Transcription

1 COMPUTATIONAL OPTIMISATION OF TARGETED DNA SEQUENCING FOR CANCER DETECTION Pierre Martinez, Nicholas McGranahan, Nicolai Juul Birkbak, Marco Gerlinger, Charles Swanton* SUPPLEMENTARY INFORMATION SUPPLEMENTARY FIGURE LEGENDS Supplementary Figure 1: Illustration of the hotspot region definition process. For different distance thresholds d, mutations were iteratively grouped into clusters that determined hotspot regions. In the example, the blue and yellow mutations are 13 base pairs apart and there is no reported mutation between them. Using at threshold d=1, these mutations are thus in two different hot spot regions. Increasing d to 2, all 4 mutations will be clustered together in a single hotspot region. Even if the green and red mutations are 21 base pairs apart, all 4 mutations are within 2 base pairs of at least one other mutation in the hotspot region. Any mutation less than 2 base pairs upstream of the red mutation or downstream of the green mutation would be included in the hotspot region. Supplementary Figure2: Computationally estimated sensitivity of targeted sequencing screen for the detection of specific tumor types using specific candidate genes. Left panels: percentage of tumors for each tumor type in each cohort that have at least one mutation in a gene included in panels defined by combining the best 1 to 25 specific candidate genes. Right panels: percentage of tumors for each tumor type that have at least one mutation in a gene included in the best panel of specific genes defined for a maximum length varying from to, nucleotides. Supplementary Figure 3: Proportion of in-frame mutations that are detectable and not detectable by hotspot region targeting approaches in each cohort. Each panel represents a different distance threshold d used to define the hotspot regions. P- values are given by two-tailed Fisher s exact tests. Supplementary Figure 4: Computationally estimated sensitivity of targeted SNV sequencing screen for the detection of specific tumour types using pan-cancer candidate SNVs. Percentage of tumours for each tumour type in each cohort that have at least one mutation in panels defined by iteratively combining the best 1, pan-cancer single nucleotide variants.

2 Martinez et al. Supplementary Figure 1 hotspot regions d=2 hotspot regions d=1 mutations DNA sequence * * * * d = 5 d = 13 d = 3

3 Martinez et al. Supplementary Figure 2 Discovery (TCGA early) Breast Head & Neck Lung Ade. Ovarian Thyroid Colorectal Kidney clear cell Lung Sq. Melanoma Uterus Validation (TCGA late) Validation (non TCGA) Gene panel length (number of genes) Gene panel length (kbp)

4 Martinez et al. Supplementary Figure dist = 1bp p=1.46e 89 p=.882 p=1.33e dist = 2bp p=1.85e 59 p=.13 p=4.96e dist = 5bp p=1.99e 28 p=3.7e 5 p=1.6e dist = bp p=6.19e 16 p=8.22e 11 p=1.19e dist = 2bp p=2.69e 12 p=6.77e 12 p=4.98e dist = 5bp p=2.17e 7 p=8.85e 15 p=3.48e 129 Discovery (TCGA early) Validation (TCGA late) Validation (non TCGA)

5 Martinez et al. Supplementary Figure 4 Discovery (TCGA early) 2 4 Validation (TCGA late) 2 4 Validation (non TCGA) 2 4 Number of single nucleotide substitutions Breast Colorectal Head & Neck Kidney clear cell Lung Ade. Lung Sq. Ovarian Melanoma Thyroid Uterus

Supplementary Materials for

Supplementary Materials for www.sciencetranslationalmedicine.org/cgi/content/full/7/283/283ra54/dc1 Supplementary Materials for Clonal status of actionable driver events and the timing of mutational processes in cancer evolution

More information

BWA alignment to reference transcriptome and genome. Convert transcriptome mappings back to genome space

BWA alignment to reference transcriptome and genome. Convert transcriptome mappings back to genome space Whole genome sequencing Whole exome sequencing BWA alignment to reference transcriptome and genome Convert transcriptome mappings back to genome space genomes Filter on MQ, distance, Cigar string Annotate

More information

underlying metastasis and recurrence in HNSCC, we analyzed two groups of patients. The

underlying metastasis and recurrence in HNSCC, we analyzed two groups of patients. The Supplementary Figures Figure S1. Patient cohorts and study design. To define and interrogate the genetic alterations underlying metastasis and recurrence in HNSCC, we analyzed two groups of patients. The

More information

Supplementary Tables. Supplementary Figures

Supplementary Tables. Supplementary Figures Supplementary Files for Zehir, Benayed et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients Supplementary Tables Supplementary Table 1: Sample

More information

Supplementary Figure 1. Estimation of tumour content

Supplementary Figure 1. Estimation of tumour content Supplementary Figure 1. Estimation of tumour content a, Approach used to estimate the tumour content in S13T1/T2, S6T1/T2, S3T1/T2 and S12T1/T2. Tissue and tumour areas were evaluated by two independent

More information

Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser

Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser Melissa S. Cline 1*, Brian Craft 1, Teresa Swatloski 1, Mary Goldman 1, Singer Ma 1, David Haussler 1, Jingchun Zhu 1 1 Center for Biomolecular

More information

Supplementary Figure 1: Features of IGLL5 Mutations in CLL: a) Representative IGV screenshot of first

Supplementary Figure 1: Features of IGLL5 Mutations in CLL: a) Representative IGV screenshot of first Supplementary Figure 1: Features of IGLL5 Mutations in CLL: a) Representative IGV screenshot of first intron IGLL5 mutation depicting biallelic mutations. Red arrows highlight the presence of out of phase

More information

Nature Getetics: doi: /ng.3471

Nature Getetics: doi: /ng.3471 Supplementary Figure 1 Summary of exome sequencing data. ( a ) Exome tumor normal sample sizes for bladder cancer (BLCA), breast cancer (BRCA), carcinoid (CARC), chronic lymphocytic leukemia (CLLX), colorectal

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION doi:10.1038/nature10866 a b 1 2 3 4 5 6 7 Match No Match 1 2 3 4 5 6 7 Turcan et al. Supplementary Fig.1 Concepts mapping H3K27 targets in EF CBX8 targets in EF H3K27 targets in ES SUZ12 targets in ES

More information

Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNA

Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNA www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2016 Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) DNA Supplementary Materials

More information

Supplementary Figure 1: Classification scheme for non-synonymous and nonsense germline MC1R variants. The common variants with previously established

Supplementary Figure 1: Classification scheme for non-synonymous and nonsense germline MC1R variants. The common variants with previously established Supplementary Figure 1: Classification scheme for nonsynonymous and nonsense germline MC1R variants. The common variants with previously established classifications 1 3 are shown. The effect of novel missense

More information

The 100,000 Genomes Project Harnessing the power of genomics for NHS rare disease and cancer patients

The 100,000 Genomes Project Harnessing the power of genomics for NHS rare disease and cancer patients The 100,000 Genomes Project Harnessing the power of genomics for NHS rare disease and cancer patients Dr Richard Scott, Clinical Lead for Rare Disease Dr Nirupa Murugaesu, Clinical Lead for Cancer Four

More information

GYNplus. genetic testing for hereditary ovarian and/or uterine cancer

GYNplus. genetic testing for hereditary ovarian and/or uterine cancer GYNplus genetic testing for hereditary ovarian and/or uterine cancer What Are the Causes of Hereditary Ovarian and Uterine Cancer? uterine cancer ovarian cancer sporadic 70-80% hereditary 5% Lynch syndrome

More information

Discovery Dataset. PD Liver Luminal B/ Her-2+ Letrozole. PD Supraclavicular Lymph node. PD Supraclavicular Lymph node Luminal B.

Discovery Dataset. PD Liver Luminal B/ Her-2+ Letrozole. PD Supraclavicular Lymph node. PD Supraclavicular Lymph node Luminal B. Discovery Dataset 11T pt1cpn2am1(liver) 2009 2010 Liver / Her-2+ 2011 Death Letrozole CHT pt1cpn0(sn)m0 Supraclavicular Lymph node Death 12T 2003 2006 2006 2008 Anastrozole Local RT+Examestane Fulvestrant

More information

Protein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies

Protein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies Protein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies Dr. Maricel G. Kann Assistant Professor Dept of Biological Sciences UMBC 2 The term protein domain

More information

Variant Classification. Author: Mike Thiesen, Golden Helix, Inc.

Variant Classification. Author: Mike Thiesen, Golden Helix, Inc. Variant Classification Author: Mike Thiesen, Golden Helix, Inc. Overview Sequencing pipelines are able to identify rare variants not found in catalogs such as dbsnp. As a result, variants in these datasets

More information

Nature Genetics: doi: /ng Supplementary Figure 1

Nature Genetics: doi: /ng Supplementary Figure 1 Supplementary Figure 1 Expression deviation of the genes mapped to gene-wise recurrent mutations in the TCGA breast cancer cohort (top) and the TCGA lung cancer cohort (bottom). For each gene (each pair

More information

Enterprise Interest Thermo Fisher Scientific / Employee

Enterprise Interest Thermo Fisher Scientific / Employee Enterprise Interest Thermo Fisher Scientific / Employee A next-generation sequencing assay to estimate tumor mutation load from FFPE research samples Fiona Hyland. Director of R&D, Bioinformatics Clinical

More information

Breast cancer. Risk factors you cannot change include: Treatment Plan Selection. Inferring Transcriptional Module from Breast Cancer Profile Data

Breast cancer. Risk factors you cannot change include: Treatment Plan Selection. Inferring Transcriptional Module from Breast Cancer Profile Data Breast cancer Inferring Transcriptional Module from Breast Cancer Profile Data Breast Cancer and Targeted Therapy Microarray Profile Data Inferring Transcriptional Module Methods CSC 177 Data Warehousing

More information

User s Manual Version 1.0

User s Manual Version 1.0 User s Manual Version 1.0 #639 Longmian Avenue, Jiangning District, Nanjing,211198,P.R.China. http://tcoa.cpu.edu.cn/ Contact us at xiaosheng.wang@cpu.edu.cn for technical issue and questions Catalogue

More information

AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits

AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits Accelerating clinical research Next-generation sequencing (NGS) has the ability to interrogate many different genes and detect

More information

SUPPLEMENTARY APPENDIX

SUPPLEMENTARY APPENDIX SUPPLEMENTARY APPENDIX 1) Supplemental Figure 1. Histopathologic Characteristics of the Tumors in the Discovery Cohort 2) Supplemental Figure 2. Incorporation of Normal Epidermal Melanocytic Signature

More information

The Role of Genetics in Ovarian Cancer Screening. Dawn DeLozier, Ph.D. Medical Geneticist, SAMC Associate Professor UCSF-Fresno

The Role of Genetics in Ovarian Cancer Screening. Dawn DeLozier, Ph.D. Medical Geneticist, SAMC Associate Professor UCSF-Fresno The Role of Genetics in Ovarian Cancer Screening Dawn DeLozier, Ph.D. Medical Geneticist, SAMC Associate Professor UCSF-Fresno How Much Breast and Ovarian Cancer Is Hereditary? 15%-20% 5%-10% Breast Cancer

More information

Genomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France

Genomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France Genomic tests to personalize therapy of metastatic breast cancers Fabrice ANDRE Gustave Roussy Villejuif, France Future application of genomics: Understand the biology at the individual scale Patients

More information

Supplementary Figure 1. Metabolic landscape of cancer discovery pipeline. RNAseq raw counts data of cancer and healthy tissue samples were downloaded

Supplementary Figure 1. Metabolic landscape of cancer discovery pipeline. RNAseq raw counts data of cancer and healthy tissue samples were downloaded Supplementary Figure 1. Metabolic landscape of cancer discovery pipeline. RNAseq raw counts data of cancer and healthy tissue samples were downloaded from TCGA and differentially expressed metabolic genes

More information

SUPPLEMENTARY FIGURES: Supplementary Figure 1

SUPPLEMENTARY FIGURES: Supplementary Figure 1 SUPPLEMENTARY FIGURES: Supplementary Figure 1 Supplementary Figure 1. Glioblastoma 5hmC quantified by paired BS and oxbs treated DNA hybridized to Infinium DNA methylation arrays. Workflow depicts analytic

More information

AVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB

AVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB Analysis Kits Next-generation performance in liquid biopsies 2 Accelerating clinical research From liquid biopsy to next-generation

More information

Epidemiology in Texas 2006 Annual Report. Cancer

Epidemiology in Texas 2006 Annual Report. Cancer Epidemiology in Texas 2006 Annual Report Cancer Epidemiology in Texas 2006 Annual Report Page 94 Cancer Incidence and Mortality in Texas, 2000-2004 The Texas Department of State Health Services Texas Cancer

More information

Genome. Institute. GenomeVIP: A Genomics Analysis Pipeline for Cloud Computing with Germline and Somatic Calling on Amazon s Cloud. R. Jay Mashl.

Genome. Institute. GenomeVIP: A Genomics Analysis Pipeline for Cloud Computing with Germline and Somatic Calling on Amazon s Cloud. R. Jay Mashl. GenomeVIP: the Genome Institute at Washington University A Genomics Analysis Pipeline for Cloud Computing with Germline and Somatic Calling on Amazon s Cloud R. Jay Mashl October 20, 2014 Turnkey Variant

More information

Nature Genetics: doi: /ng Supplementary Figure 1. SEER data for male and female cancer incidence from

Nature Genetics: doi: /ng Supplementary Figure 1. SEER data for male and female cancer incidence from Supplementary Figure 1 SEER data for male and female cancer incidence from 1975 2013. (a,b) Incidence rates of oral cavity and pharynx cancer (a) and leukemia (b) are plotted, grouped by males (blue),

More information

Transcriptional Profiles from Paired Normal Samples Offer Complementary Information on Cancer Patient Survival -- Evidence from TCGA Pan-Cancer Data

Transcriptional Profiles from Paired Normal Samples Offer Complementary Information on Cancer Patient Survival -- Evidence from TCGA Pan-Cancer Data Transcriptional Profiles from Paired Normal Samples Offer Complementary Information on Cancer Patient Survival -- Evidence from TCGA Pan-Cancer Data Supplementary Materials Xiu Huang, David Stern, and

More information

Correlation of gene expression and associated mutation profiles of APOBEC3A, chemosensitivity of cancer cell lines to drug treatment

Correlation of gene expression and associated mutation profiles of APOBEC3A, chemosensitivity of cancer cell lines to drug treatment Vural et al. Human Genomics (2018) 12:20 https://doi.org/10.1186/s40246-018-0150-x PRIMARY RESEARCH Open Access Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1,

More information

CANCER GENETICS PROVIDER SURVEY

CANCER GENETICS PROVIDER SURVEY Dear Participant, Previously you agreed to participate in an evaluation of an education program we developed for primary care providers on the topic of cancer genetics. This is an IRB-approved, CDCfunded

More information

Whole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute

Whole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute Whole Genome and Transcriptome Analysis of Anaplastic Meningioma Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute Outline Anaplastic meningioma compared to other cancers Whole genomes

More information

Introduction. Introduction

Introduction. Introduction Introduction We are leveraging genome sequencing data from The Cancer Genome Atlas (TCGA) to more accurately define mutated and stable genes and dysregulated metabolic pathways in solid tumors. These efforts

More information

GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer

GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer Causes of Hereditary Ovarian and Uterine Cancer uterine cancer ovarian cancer Sporadic 75-90% Sporadic 70-80% Hereditary, 5% Lynch syndrome

More information

BRCAplus. genetic testing for hereditary breast cancer

BRCAplus. genetic testing for hereditary breast cancer BRCAplus genetic testing for hereditary breast cancer Developed in collaboration with Fox Chase Cancer Center and the Arcadia University Genetic Counseling Program. Causes of Hereditary Breast Cancer familial

More information

Cancer Alliance Data Pack

Cancer Alliance Data Pack Humber, Coast and Vale Cancer Alliance Data Pack By February 18 Version 1.2 Produced by the Cancer Alliance Data, Evidence and Analysis Service (CADEAS) For any enquiries contact: england.cadeas@nhs.net

More information

Mouse Clec9a ORF sequence

Mouse Clec9a ORF sequence Mouse Clec9a gene LOCUS NC_72 13843 bp DNA linear CON 1-JUL-27 DEFINITION Mus musculus chromosome 6, reference assembly (C57BL/6J). ACCESSION NC_72 REGION: 129358881-129372723 Mouse Clec9a ORF sequence

More information

Expert-guided Visual Exploration (EVE) for patient stratification. Hamid Bolouri, Lue-Ping Zhao, Eric C. Holland

Expert-guided Visual Exploration (EVE) for patient stratification. Hamid Bolouri, Lue-Ping Zhao, Eric C. Holland Expert-guided Visual Exploration (EVE) for patient stratification Hamid Bolouri, Lue-Ping Zhao, Eric C. Holland Oncoscape.sttrcancer.org Paul Lisa Ken Jenny Desert Eric The challenge Given - patient clinical

More information

Towards a Universal Law Controlling All Human Cancer Chromosome LOH Deletions, Perspectives in Prostate and Breast Cancers Screening

Towards a Universal Law Controlling All Human Cancer Chromosome LOH Deletions, Perspectives in Prostate and Breast Cancers Screening Research Article imedpub Journals www.imedpub.com Abstract Towards a Universal Law Controlling All Human Cancer Chromosome LOH Deletions, Perspectives in Prostate and Breast Cancers Screening Background:

More information

SVIM: Structural variant identification with long reads DAVID HELLER MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS, BERLIN JUNE 2O18, SMRT LEIDEN

SVIM: Structural variant identification with long reads DAVID HELLER MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS, BERLIN JUNE 2O18, SMRT LEIDEN SVIM: Structural variant identification with long reads DAVID HELLER MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS, BERLIN JUNE 2O18, SMRT LEIDEN Structural variation (SV) Variants larger than 50bps Affect

More information

Frequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R

Frequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB

More information

GENETIC TESTING: WHAT DOES IT REALLY TELL YOU? Lori L. Ballinger, MS, CGC Licensed Genetic Counselor University of New Mexico Cancer Center

GENETIC TESTING: WHAT DOES IT REALLY TELL YOU? Lori L. Ballinger, MS, CGC Licensed Genetic Counselor University of New Mexico Cancer Center GENETIC TESTING: WHAT DOES IT REALLY TELL YOU? Lori L. Ballinger, MS, CGC Licensed Genetic Counselor University of New Mexico Cancer Center Definitions: DNA: The material found in our cells - the instructions

More information

Nature Medicine: doi: /nm.4439

Nature Medicine: doi: /nm.4439 Figure S1. Overview of the variant calling and verification process. This figure expands on Fig. 1c with details of verified variants identification in 547 additional validation samples. Somatic variants

More information

Feasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015

Feasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015 Feasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015 Study Name Feasibility of Patient Population for proposed

More information

Gene-microRNA network module analysis for ovarian cancer

Gene-microRNA network module analysis for ovarian cancer Gene-microRNA network module analysis for ovarian cancer Shuqin Zhang School of Mathematical Sciences Fudan University Oct. 4, 2016 Outline Introduction Materials and Methods Results Conclusions Introduction

More information

NGS in tissue and liquid biopsy

NGS in tissue and liquid biopsy NGS in tissue and liquid biopsy Ana Vivancos, PhD Referencias So, why NGS in the clinics? 2000 Sanger Sequencing (1977-) 2016 NGS (2006-) ABIPrism (Applied Biosystems) Up to 2304 per day (96 sequences

More information

Clustered mutations of oncogenes and tumor suppressors.

Clustered mutations of oncogenes and tumor suppressors. Supplementary Figure 1 Clustered mutations of oncogenes and tumor suppressors. For each oncogene (red dots) and tumor suppressor (blue dots), the number of mutations found in an intramolecular cluster

More information

ARTICLE RESEARCH. Macmillan Publishers Limited. All rights reserved

ARTICLE RESEARCH. Macmillan Publishers Limited. All rights reserved Extended Data Figure 6 Annotation of drivers based on clinical characteristics and co-occurrence patterns. a, Putative drivers affecting greater than 10 patients were assessed for enrichment in IGHV mutated

More information

Identification of Tissue Independent Cancer Driver Genes

Identification of Tissue Independent Cancer Driver Genes Identification of Tissue Independent Cancer Driver Genes Alexandros Manolakos, Idoia Ochoa, Kartik Venkat Supervisor: Olivier Gevaert Abstract Identification of genomic patterns in tumors is an important

More information

Trends and disparities in cancer in Aotearoa/ NZ

Trends and disparities in cancer in Aotearoa/ NZ Trends and disparities in cancer in Aotearoa/ NZ Professor Diana Sarfati #cancercrossroads @DiSarfati Why cancer? Estimated number of incident cases from 2018 to 2040 in New Zealand, all cancers, both

More information

Cancer genetics

Cancer genetics Cancer genetics General information about tumorogenesis. Cancer induced by viruses. The role of somatic mutations in cancer production. Oncogenes and Tumor Suppressor Genes (TSG). Hereditary cancer. 1

More information

Personalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients

Personalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients Personalised cancer care Information for Medical Specialists A new way to unlock treatment options for your patients Contents Optimised for clinical benefit 4 Development history 4 Full FIND IT panel vs

More information

CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION

CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer our most comprehensive oncogenetics panel for hereditary mutations Hereditary pathogenic variants confer an increased risk of developing

More information

The Cancer Genome Atlas Pan-cancer analysis Katherine A. Hoadley

The Cancer Genome Atlas Pan-cancer analysis Katherine A. Hoadley The Cancer Genome Atlas Pan-cancer analysis Katherine A. Hoadley Department of Genetics Lineberger Comprehensive Cancer Center The University of North Carolina at Chapel Hill What is TCGA? The Cancer Genome

More information

Large-scale identity-by-descent mapping discovers rare haplotypes of large effect. Suyash Shringarpure 23andMe, Inc. ASHG 2017

Large-scale identity-by-descent mapping discovers rare haplotypes of large effect. Suyash Shringarpure 23andMe, Inc. ASHG 2017 Large-scale identity-by-descent mapping discovers rare haplotypes of large effect Suyash Shringarpure 23andMe, Inc. ASHG 2017 1 Why care about rare variants of large effect? Months from randomization 2

More information

ciap using fragment based drug discovery

ciap using fragment based drug discovery Discovery of a potent dual antagonist of both XIAP and ciap using fragment based drug discovery Gianni Chessari, PhD TAT Congress 2012 Disclosures I am an employee of Astex Pharmaceuticals I will present

More information

Characterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser

Characterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser Characterisation of structural variation in breast cancer genomes using paired-end sequencing on the Illumina Genome Analyser Phil Stephens Cancer Genome Project Why is it important to study cancer? Why

More information

patient guide RenalNext genetic testing for hereditary kidney cancer Because knowing your risk can mean early detection and prevention

patient guide RenalNext genetic testing for hereditary kidney cancer Because knowing your risk can mean early detection and prevention patient guide RenalNext genetic testing for hereditary kidney cancer Because knowing your risk can mean early detection and prevention Know the Basics Risk factors for developing kidney cancer include

More information

Abstract. Optimization strategy of Copy Number Variant calling using Multiplicom solutions APPLICATION NOTE. Introduction

Abstract. Optimization strategy of Copy Number Variant calling using Multiplicom solutions APPLICATION NOTE. Introduction Optimization strategy of Copy Number Variant calling using Multiplicom solutions Michael Vyverman, PhD; Laura Standaert, PhD and Wouter Bossuyt, PhD Abstract Copy number variations (CNVs) represent a significant

More information

PSSV User Manual (V1.0)

PSSV User Manual (V1.0) PSSV User Manual (V1.0) 1. Introduction A novel pattern-based probabilistic approach, PSSV, is developed to identify somatic structural variations from WGS data. Specifically, discordant and concordant

More information

Journal: Nature Methods

Journal: Nature Methods Journal: Nature Methods Article Title: Network-based stratification of tumor mutations Corresponding Author: Trey Ideker Supplementary Item Supplementary Figure 1 Supplementary Figure 2 Supplementary Figure

More information

OBESITY AND CANCER RISK

OBESITY AND CANCER RISK OBESITY AND CANCER RISK Obesity is a condition in which a person has an abnormally high and unhealthy proportion of body fat. According to the Kansas Behavioral Risk Factor Surveillance System, in 21,

More information

OBESITY AND CANCER RISK

OBESITY AND CANCER RISK OBESITY AND CANCER RISK Obesity is a condition in which a person has an abnormally high and unhealthy proportion of body fat. According to the Kansas Behavioral Risk Factor Surveillance System, in 212,

More information

6/12/2018. Disclosures. Clinical Genomics The CLIA Lab Perspective. Outline. COH HopeSeq Heme Panels

6/12/2018. Disclosures. Clinical Genomics The CLIA Lab Perspective. Outline. COH HopeSeq Heme Panels Clinical Genomics The CLIA Lab Perspective Disclosures Raju K. Pillai, M.D. Hematopathologist / Molecular Pathologist Director, Pathology Bioinformatics City of Hope National Medical Center, Duarte, CA

More information

NGS ONCOPANELS: FDA S PERSPECTIVE

NGS ONCOPANELS: FDA S PERSPECTIVE NGS ONCOPANELS: FDA S PERSPECTIVE CBA Workshop: Biomarker and Application in Drug Development August 11, 2018 Rockville, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration

More information

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage Aaron M Newman1,2,7, Scott V Bratman1,3,7, Jacqueline To3, Jacob F Wynne3, Neville C W Eclov3, Leslie A Modlin3,

More information

Appendix 1 (as supplied by the authors): Supplementary data

Appendix 1 (as supplied by the authors): Supplementary data Appendix 1 (as supplied by the authors): Supplementary data I. Cancer prevalence in Canada We obtained 10 year person based cancer prevalence rates for all of Canada for some years of our study period

More information

List of Available TMAs in the PRN

List of Available TMAs in the PRN TMA RPCI_BrainCa01 RPCI_BrCa03 RPCI_BrCa04 RPCI_BrCa05 RPCI_BrCa0 RPCI_BrCa07 RPCI_BrCa08 RPCI_BrCa15 RPCI_BrCa1 RPCI_BrCa17 RPCI_BrCa18 RPCI_BrCa19 RPCI_BrCa20 RPCI_BrCa21 RPCI_BrCa24 RPCI_BrCa25 RPCI_BrCa2

More information

GENETIC TESTING FOR PREDICTING RISK OF NONFAMILIAL BREAST CANCER

GENETIC TESTING FOR PREDICTING RISK OF NONFAMILIAL BREAST CANCER Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent upon

More information

Information for You and Your Family

Information for You and Your Family Information for You and Your Family What is Prevention? Cancer prevention is action taken to lower the chance of getting cancer. In 2017, more than 1.6 million people will be diagnosed with cancer in the

More information

GENETIC TESTING: WHAT DOES IT REALLY TELL YOU? Shawnia Ryan, MS, LCGC Senior Genetic Counselor University of New Mexico Cancer Center

GENETIC TESTING: WHAT DOES IT REALLY TELL YOU? Shawnia Ryan, MS, LCGC Senior Genetic Counselor University of New Mexico Cancer Center GENETIC TESTING: WHAT DOES IT REALLY TELL YOU? Shawnia Ryan, MS, LCGC Senior Genetic Counselor University of New Mexico Cancer Center What is genetic counseling? communication process address individual

More information

Integration of Cancer Genome into GECCO- Genetics and Epidemiology of Colorectal Cancer Consortium

Integration of Cancer Genome into GECCO- Genetics and Epidemiology of Colorectal Cancer Consortium Integration of Cancer Genome into GECCO- Genetics and Epidemiology of Colorectal Cancer Consortium Ulrike Peters Fred Hutchinson Cancer Research Center University of Washington U01-CA137088-05, PI: Peters

More information

Figure 1.1 PHITS geometry for PTB irradiations with: broad beam, upper panel; mono energetic beams, lower panel. Pictures of the setups and of the

Figure 1.1 PHITS geometry for PTB irradiations with: broad beam, upper panel; mono energetic beams, lower panel. Pictures of the setups and of the Figure 1.1 PHITS geometry for PTB irradiations with: broad beam, upper panel; mono energetic beams, lower panel. Pictures of the setups and of the PMMA ring holder with 7 containers are also shown. Relative

More information

Nature Biotechnology: doi: /nbt.1904

Nature Biotechnology: doi: /nbt.1904 Supplementary Information Comparison between assembly-based SV calls and array CGH results Genome-wide array assessment of copy number changes, such as array comparative genomic hybridization (acgh), is

More information

6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017

6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017 Genetics 101 Hereditary Breast and Ovarian Cancer 2017 Rebecca Sutphen, MD, FACMG Professor, College of Medicine President & Chief Medical Officer INVASIVE CANCER GENETICALLY ALTERED CELL HYPERPLASIA DYSPLASIA

More information

Molecular Imaging and Cancer

Molecular Imaging and Cancer Molecular Imaging and Cancer Cancer causes one in every four deaths in the United States, second only to heart disease. According to the U.S. Department of Health and Human Services, more than 512,000

More information

NGS IN ONCOLOGY: FDA S PERSPECTIVE

NGS IN ONCOLOGY: FDA S PERSPECTIVE NGS IN ONCOLOGY: FDA S PERSPECTIVE ASQ Biomed/Biotech SIG Event April 26, 2018 Gaithersburg, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration (FDA) Center for

More information

patient guide MelanomaNext genetic testing for hereditary melanoma Because knowing your risk can mean early detection and prevention

patient guide MelanomaNext genetic testing for hereditary melanoma Because knowing your risk can mean early detection and prevention patient guide MelanomaNext genetic testing for hereditary melanoma Because knowing your risk can mean early detection and prevention Know the Basics The average age of diagnosis for melanoma is 63 YEARS

More information

Performance Characteristics BRCA MASTR Plus Dx

Performance Characteristics BRCA MASTR Plus Dx Performance Characteristics BRCA MASTR Plus Dx with drmid Dx for Illumina NGS systems Manufacturer Multiplicom N.V. Galileïlaan 18 2845 Niel Belgium Table of Contents 1. Workflow... 4 2. Performance Characteristics

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Henson KE, Brock R, Charnock J, Wickramasinghe B, Will O, Pitman A. Risk of suicide after cancer diagnosis in England. JAMA Psychiatry. Published online November 21, 2018.

More information

De Novo Viral Quasispecies Assembly using Overlap Graphs

De Novo Viral Quasispecies Assembly using Overlap Graphs De Novo Viral Quasispecies Assembly using Overlap Graphs Alexander Schönhuth joint with Jasmijn Baaijens, Amal Zine El Aabidine, Eric Rivals Milano 18th of November 2016 Viral Quasispecies Assembly: HaploClique

More information

Phase-specific Costs of Cancer Care in Ontario

Phase-specific Costs of Cancer Care in Ontario Phase-specific Costs of Cancer Care in Ontario Canadian Association of Health Services and Policy Research Conference Session: D5 Cancer Care Wednesday May 29 2013 Claire de Oliveira, M.A. PhD Background

More information

Supplementary Figure 1. Spitzoid Melanoma with PPFIBP1-MET fusion. (a) Histopathology (4x) shows a domed papule with melanocytes extending into the

Supplementary Figure 1. Spitzoid Melanoma with PPFIBP1-MET fusion. (a) Histopathology (4x) shows a domed papule with melanocytes extending into the Supplementary Figure 1. Spitzoid Melanoma with PPFIBP1-MET fusion. (a) Histopathology (4x) shows a domed papule with melanocytes extending into the deep dermis. (b) The melanocytes demonstrate abundant

More information

David Tamborero, PhD

David Tamborero, PhD David Tamborero, PhD Lopez-Bigas' lab Study of Tumor Genomes Study of Tumor Genomes Study sequencing data of tumors to understand the biological mechanisms shaping the mutational processes observed at

More information

Health Systems Adoption of Personalized Medicine: Promise and Obstacles. Scott Ramsey Fred Hutchinson Cancer Research Center Seattle, WA

Health Systems Adoption of Personalized Medicine: Promise and Obstacles. Scott Ramsey Fred Hutchinson Cancer Research Center Seattle, WA Health Systems Adoption of Personalized Medicine: Promise and Obstacles Scott Ramsey Fred Hutchinson Cancer Research Center Seattle, WA Cancer Pharmaceutical Pricing Bach P. NEJM 2009;360:626 Opportunities

More information

Nature Genetics: doi: /ng Supplementary Figure 1. Rates of different mutation types in CRC.

Nature Genetics: doi: /ng Supplementary Figure 1. Rates of different mutation types in CRC. Supplementary Figure 1 Rates of different mutation types in CRC. (a) Stratification by mutation type indicates that C>T mutations occur at a significantly greater rate than other types. (b) As for the

More information

Nature Medicine: doi: /nm.3967

Nature Medicine: doi: /nm.3967 Supplementary Figure 1. Network clustering. (a) Clustering performance as a function of inflation factor. The grey curve shows the median weighted Silhouette widths for varying inflation factors (f [1.6,

More information

Foreign antigens in human cancers

Foreign antigens in human cancers Foreign antigens in human cancers Lorenzo Fanchi PhD student, Ton Schumacher Lab ESMO Preceptorship on Immuno-Oncology May 26th, 2017 IMMUNE CHECKPOINT INHIBITION SHOWS CLINICAL BENEFIT IN DIFFERENT TUMOR

More information

Result Navigator. Positive Test Result: PTEN. After a positive test result, there can be many questions about what to do next. Navigate Your Results

Result Navigator. Positive Test Result: PTEN. After a positive test result, there can be many questions about what to do next. Navigate Your Results Result Navigator Positive Test Result: PTEN Positive test results identify a change, or misspelling, of DNA that is known or predicted to cause an increased risk for cancer. DNA is the blueprint of life

More information

iplex genotyping IDH1 and IDH2 assays utilized the following primer sets (forward and reverse primers along with extension primers).

iplex genotyping IDH1 and IDH2 assays utilized the following primer sets (forward and reverse primers along with extension primers). Supplementary Materials Supplementary Methods iplex genotyping IDH1 and IDH2 assays utilized the following primer sets (forward and reverse primers along with extension primers). IDH1 R132H and R132L Forward:

More information

Plasma-Based Molecular Testing for Early Detection of Lung Cancer

Plasma-Based Molecular Testing for Early Detection of Lung Cancer Plasma-Based Molecular Testing for Early Detection of Lung Cancer November 8, 2018 Eric Fung, MD, PhD GRAIL, Inc. Menlo Park, California, USA Disclosures Eric Fung, MD, PhD is an employee of GRAIL and

More information

A Versatile Algorithm for Finding Patterns in Large Cancer Cell Line Data Sets

A Versatile Algorithm for Finding Patterns in Large Cancer Cell Line Data Sets A Versatile Algorithm for Finding Patterns in Large Cancer Cell Line Data Sets James Jusuf, Phillips Academy Andover May 21, 2017 MIT PRIMES The Broad Institute of MIT and Harvard Introduction A quest

More information

Tableau user guide for all Official Statistics

Tableau user guide for all Official Statistics Health Intelligence Division, Public Health Wales Uned Deallusrwydd a Gwyliadwriaeth Canser Cymru Cyfadran Deallusrwydd Iechyd, Iechyd Cyhoeddus Cymru Tableau user guide for all Official Statistics There

More information

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT OGEN (AN ESTROGEN HORMONE)?

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT OGEN (AN ESTROGEN HORMONE)? PATIENT INFORMATION (Updated July 2006) OGEN estropipate tablets, USP Read this PATIENT INFORMATION before you start taking OGEN and read what you get each time you refill OGEN. There may be new information.

More information

Genetic alterations of histone lysine methyltransferases and their significance in breast cancer

Genetic alterations of histone lysine methyltransferases and their significance in breast cancer Genetic alterations of histone lysine methyltransferases and their significance in breast cancer Supplementary Materials and Methods Phylogenetic tree of the HMT superfamily The phylogeny outlined in the

More information

Supplementary Figures

Supplementary Figures Supplementary Figures Supplementary Figure 1. Pan-cancer analysis of global and local DNA methylation variation a) Variations in global DNA methylation are shown as measured by averaging the genome-wide

More information

Cancer Gene Panels. Dr. Andreas Scherer. Dr. Andreas Scherer President and CEO Golden Helix, Inc. Twitter: andreasscherer

Cancer Gene Panels. Dr. Andreas Scherer. Dr. Andreas Scherer President and CEO Golden Helix, Inc. Twitter: andreasscherer Cancer Gene Panels Dr. Andreas Scherer Dr. Andreas Scherer President and CEO Golden Helix, Inc. scherer@goldenhelix.com Twitter: andreasscherer About Golden Helix - Founded in 1998 - Main outside investor:

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION doi:10.1038/nature10913 Supplementary Figure 1 2F o -F c electron density maps of cognate and near-cognate trna Leu 2 in the A site of the 70S ribosome. The maps are contoured at 1.2 sigma and some of

More information